Tango Therapeutics prices $600M upsized public offering
Tango Therapeutics priced an upsized underwritten public offering of 18,166,667 common shares and 1,833,395 pre-funded warrants to raise $600 million. The shares and warrants are priced at $30.00 and $29.999 respectively, with the deal expected to close on June 11, 2026.
*this image is generated using AI for illustrative purposes only.
Tango Therapeutics, Inc. has priced an upsized underwritten public offering expected to generate approximately $600 million in gross proceeds to fund its clinical-stage biotechnology operations focused on precision cancer medicines. The offering comprises 18,166,667 shares of common stock and pre-funded warrants to purchase up to 1,833,395 shares, priced at $30.00 and $29.999 respectively. The transaction is scheduled to close on or about June 11, 2026, subject to customary closing conditions.
J.P. Morgan, Leerink Partners, Cantor, and Stifel are acting as joint bookrunning managers for the offering. Tango has granted the underwriters a 30-day option to purchase up to an additional 3,000,009 shares of common stock at the public offering price, less the underwriting discount. All securities are being sold by Tango Therapeutics pursuant to an effective shelf registration statement previously filed with the U.S. Securities and Exchange Commission (SEC).
The offering details are summarized below:
| Component | Details |
|---|---|
| Common Stock Shares | 18,166,667 |
| Pre-Funded Warrants | 1,833,395 |
| Price per Share | $30.00 |
| Price per Warrant | $29.999 |
| Gross Proceeds | ~$600 million |
| Additional Option | 3,000,009 shares |
| Expected Closing | June 11, 2026 |
| Underwriters | J.P. Morgan, Leerink Partners, Cantor, Stifel |
Tango Therapeutics leverages the genetic principle of synthetic lethality to discover and develop therapies targeting critical cancer mechanisms.
How will Tango Therapeutics allocate the $600 million in proceeds across its clinical-stage pipeline?
What are the key milestones expected from Tango's synthetic lethality-based precision cancer medicines in the near term?
How might the successful completion of this offering influence investor sentiment toward other biotech firms pursuing similar strategies?
16
Create Custom Screeners 
Access 200+ Pre-built Filters 
Use 50+ Readymade Screener 
